Qilu Pharmaceutical
↗8888 Lvyou Road, High-tech Zone, Jinan, China
Qilu Pharmaceutical is one of China's leading vertically integrated pharmaceutical companies, established in 1958 and headquartered in Jinan. The company specializes in the development, manufacturing, and commercialization of active pharmaceutical ingredients (APIs), finished dosage forms, generic drugs, biosimilars, and innovative therapeutics. With over 38,000 employees worldwide and 12 subsidiaries across multiple continents, Qilu operates 11 manufacturing sites certified by FDA, EMA, MHRA, PMDA, and TGA. The company ranks among the top 3 pharmaceutical companies in China in 2024 and maintains global presence with products exported to over 110 countries.
CLASSIFICATION
Company Type:Pharma
Therapeutic Areas:
Industry:Pharmaceuticals
Sub-Industry:Vertically Integrated Pharma - APIs, Generics, Biosimilars, Innovative Therapeutics
SIZE & FINANCIALS
Employees:10000+
Founded:1958
Ownership:private
Status:operating
PIPELINE
Stage:Discovery through Commercial
Lead Drug Stage:Phase 3 (QL1706, WX-0593 Iruplinalkib)
Modalities:Small molecule, mAb, Bifunctional antibody (MabPair), ADC, Biosimilar, Generic
Active Trials:526
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:Qilu King-Phar (API manufacturing), Qilu Antibiotics, Qilu Pharmaceutical Spain, QILU Regor Therapeutics (founded 2018, cell therapy focus), Shanghai Qilu Pharmaceutical Research Center, Qilu Pharmaceutical (Inner Mongolia), Qilu Pharmaceutical (HaiNan), 11 additional subsidiaries
Key Partnerships:Insilico Medicine (~$120M cardiometabolic drug development, Jan 2026), Minghui Pharmaceutical (MHB088C B7-H3 ADC, Greater China, May 2025), Arbutus Biopharma (AB-729 HBV, Greater China, $40M upfront + $245M milestones), Laekna (LAE002 afuresertib breast cancer, Greater China, Nov 2025), Lisata Therapeutics (Certepetide PDAC - TERMINATED Jan 2026), CellOrigin Biotech (CAR-iMAC cell therapy collaboration)
COMPETITION
Position:Leader
Competitors:Sinopharm Group, Shanghai Pharmaceutical Co., Jiuzhoutong Group Corp., Luyan Pharma, Laurus Labs, Neuland, NGL Fine Chem
LEADERSHIP
Key Executives:
Xiayang Qiu - Founder & CEO
Li Yan - General Manager
Oliver Kong - Chief Medical Officer, Corporate Vice President
Joyce Pei - Executive Vice President, Business Development
Chaoyu Xie - Head of Regulatory Affairs, VP Innovation Institute
LINKS
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Qilu Pharmaceutical and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Qilu Pharmaceutical. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.